Inorganic Chemistry
Article
3
i
precipitate was observed during the reaction, then it was filtered and
washed with acetonitrile (2 × 2 mL) before removal of the solvent
from the filtrate.
iPr−CH), 6.12 (d, 2 H, J = 7.3 Hz, (ii) Pr−CH3), 4.18 (s, 3 H, (i)
NCH3), 4.17 (s, 3 H, (ii) NCH3), 2.85 (s, 3 H, (i) COCH3), 2.81 (s,
3 H, (ii) COCH3), 1.74 (d, 3J = 7.1 Hz, (i) iPr−CH3), 1.72z (d, 3J =
7.3 Hz, (ii) iPr−CH3) ppm. 13C{1H} NMR (126 MHz, CDCl3, AT):
δ = 176.0 ((i) NCOCH3), 175.9 ((ii) NCOCH3), 162.6 ((i, ii) NC),
161.79 ((i) HEP), 161.76 ((ii) HEP) 142.7 ((i) Py−C), 142.6 ((ii)
Py−C), 142.34 ((ii) Py−C), 142.30 ((i) Py−C), 134.1 ((ii) Ar−C),
134.0 ((i) Ar−C), 129.7 ((ii) Py−C), 129.6 ((i) Py−C), 122.8 ((i)
Ar−C), 122.7 ((ii) Ar−C), 119.8 ((i) Py−C), 119.7 ((ii) Py−C),
113.11 ((ii) Ar−C), 113.09 ((i) Ar−C), 55.2 ((ii) iPr−CH), 55.1 ((i)
iPr−CH), 46.1 ((ii) NCH3), 45.8 ((i) NCH3), 29.4 ((ii) COCH3),
General Complexation Route B. A solution of the ligand
precursor (0.30 mmol, 1.0 equiv) in acetonitrile (3 mL) was added to
a solution of palladium-dimer I (0.141 g, 0.15 mmol, 0.5 equiv) in
acetonitrile (12 mL). For precursors with a lower solubility, a few
drops of dimethylsulfoxide were added to the dispersion in
acetonitrile until the precursor was fully dissolved. Subsequently,
silver(I) oxide (0.035 g, 0.15 mmol, 0.5 equiv) was added to the
reaction mixture. After 3 h stirring, the solid formed was filtered and
washed with acetonitrile (4 × 5 mL). The solvent of the filtrate was
removed, and the remaining solid was dried in vacuo for 12 h at 50 °C.
Iodide containing precursors were mixed with silver(I) oxide before
adding the mixture to a solution of palladium-dimer I.
Dibromido(1,3-diisopropylbenzimidazolin-2-ylidene)(N-(1-
methylpyridin-4-ylidene)acetamide)palladium(II) (8). Using
route B, the product was obtained as an orange powder. Orange
single crystals could be obtained from a solution of chloroform
layered with ether and hexane. Yield: 0.140 g (0.23 mmol, 76%). Two
sets of signals (i and ii) are seen in the NMR spectra.
C21H28Br2N4OPd (M = 618.71 g mol−1). 1H NMR (500 MHz,
CDCl3): δ = 8.51 (dm, 2 H, (i) Py−H), 8.47 (dm, 2 H, (ii) Py−H),
i
i
28.8 ((i) COCH3), 21.2 ((i) Pr−CH3), 21.1 ((ii) Pr−CH3), 20.7
i
((ii) Pr−CH3) ppm. HRMS (ESI, positive ions): calcd for [M +
Na]+, C21H28Br2N4NaOPd, m/z = 638.9557. Found, m/z = 638.9562.
Dibromido(1,3-diisopropylbenzimidazolin-2-ylidene)(N-(1-
benzylpyridin-4-ylidene)acetamide)palladium(II) (11). Follow-
ing route B, the product was obtained as a yellow powder. Single
crystals were obtained from a solution of chloroform layered with
diethyl ether. C27H32Br2N4OPd (M = 694.81 g mol−1). Yield: 0.207 g
(0.30 mmol, 99%). 1H NMR (500 MHz, CDCl3, AT): δ = 8.61 (t, 2
H, 3J = 7.5 Hz, Py−H), 7.80 (d, 2 H, 3J = 7.5 Hz, Py−H), 7.57 (dd, 2
3
4
H, J = 6.2 Hz, J = 3.2 Hz, Ar−H), 7.44−7.37 (m, 3 H, Bn−H),
3
4
7.30−7.26 (m, 2 H, Bn−H), 7.20 (dd, 2 H J = 6.2 Hz, J = 3.2 Hz,
3
4
Ar−H), 6.45 (br. s, 1 H, iPr−CH), 6.38 (br. s, 1 H, iPr−CH), 5.22 (s,
7.77−7.71 (m, 2 H, Py−H), 7.57 (dd, 2 H, J = 6.2 Hz, J = 3.2 Hz,
3
3
i
Ar−H), 7.20 (dd, 2 H, J = 6.2 Hz, J = 3.2 Hz, Ar−H), 6.60−6.40
2 H, CH2), 3.12 (s, 3 H, COCH3), 1.81 (d 12 H, Pr−CH3) ppm.
i
i
13C{1H} NMR (126 MHz, CDCl3, AT): δ = 181.8 (NCOCH3), 164.6
(br. m, 2 H, Pr−CH), 6.42−6.25 (br. m, 2 H, (i) Pr−CH), 6.25−
6.12 (br. m, 2 H, (ii) iPr−CH), 3.89 (s, 3 H, (i) NCH3), 3.89 (s, 3 H,
(ii) NCH3), 3.08 (s, 2 H, (i) COCH3), 3.03 (s, 2 H, COCH3), 1.82
(HEP), 164.0 (NC), 140.5 (Py−C), 134.14 (Bn−C), 134.13 (Ar−C),
130.24 (Bn−C), 130.20 (Bn−C), 129.0 (Bn−C), 122.8 (Ar−C),
120.5 (Py−C), 113.3 (Ar−C), 62.2 (CH2), 55.1 (iPr−CH), 31.7
(COCH3), 21.4 (iPr−CH3) ppm. Anal. Calcd for C27H32Br2N4OPd:
C, 46.61, H, 4.78, N, 8.05%. Found: C, 46.05, H, 4.65, N, 8.07%.
Better values could not be obtained despite several recrystallizations.
HRMS (ESI, positive ions): calcd for [M + H]+, C27H33Br2N4OPd,
m/z = 693.0050. Found, m/z = 693.0047.
(d, 12 H, (i) Pr−CH3), 1.79 (d, 12 H, (ii) iPr−CH3) ppm. 13C{1H}
i
NMR (126 MHz, CDCl3): δ = 181.4 (NCOCH3), 164.6 (HEP),
163.9 (NC), 153.4, 145.2, 141.5, 141.3, 134.3, 134.1, 122.9, 122.8,
122.7, 120.7, 120.5, 116.4, 113.3, 55.1 (iPr−CH), 45.9 (NCH3), 31.9
i
((ii) COCH3), 31.5 ((i) COCH3), 21.4 (br., Pr−CH3) ppm. Anal.
Calcd for C21H28Br2N4OPd CHCl3: C, 35.80; H, 3.96; N, 7.59%.
Found: C, 35.82; H, 3.83; N, 7.79%. HRMS (ESI): calcd for [M +
Na]+, C21H28Br2N4NaOPd, m/z = 638.9557. Found, m/z = 638.9539.
Dibromido(1,3-diisopropylbenzimidazolin-2-ylidene)(N-(1-
methylpyridin-3-ylidene)acetamide)palladium(II) (9). After a
reaction according to route B, the product was obtained as a brown
powder, which was crystallized from a solution in chloroform layered
with diethyl ether and hexane to give red-brown single crystals.
C21H28Br2N4OPd (M = 618.71 g mol−1). Yield: 0.146 g (0.24 mmol,
Dibromido(1,3-diisopropylbenzimidazolin-3-ylidene)(N-(1-
benzylpyridin-4-ylidene)acetamide)palladium(II) (12). Precur-
sors not showing a successful conversion with silver(I) oxide were
treated with an excess of sodium hydroxide (0.15 mL, 8.7 M, 4.4
equiv) as a base. The formation of a precipitate upon base addition
could be observed for this reaction. The remaining solid after
removing the solvent was dispersed in chloroform (20 mL), and the
organic phase was washed with water (3 × 10 mL) to remove traces
of salts. After drying the organic phase over sodium sulfate for 1 h, the
solvent of the filtrate was removed, and the residue was dried in vacuo
for several hours at 50 °C. The complex was obtained as dark green
crystals after crystallization from a solution of chloroform layered with
diethyl ether. C27H32Br2N4OPd (M = 694.81 g mol−1). Yield: 0.030 g
(0.043 mmol, 14%). 1H NMR (500 MHz, CDCl3, AT): δ = 9.91 (s, 1
H, Py−H), 9.37 (dm, 1 H, Py−H), 7.69 (d, 1 H, Py−H), 7.61−7.54
(m, 3 H, Py−H, Bn−H), 7.44−7.40 (m, 3 H, Bn−H), 7.35 (dd, 2 H,
1
3
78%). H NMR (500 MHz, CDCl3): δ = 9.52 (d, 1 H J = 6.3 Hz,
Py−H), 9.26 (d, 1 H, 3J = 8.7 Hz, Py−H), 9.21 (d, 1 H, 3J = 8.7 Hz,
Py−H), 7.77 (dm, 1 H, 3J = 5.1 Hz, Py−H), 7.61 (t, 1 H, 3J = 6.3 Hz,
3
4
Py−H), 7.56 (dd, 2 H, J = 6.1 Hz, J = 3.2 Hz, Ar−H), 7.18 (dd, 2
3
4
i
H, J = 6.1 Hz, J = 3.2 Hz, Ar−H), 6.56−6.13 (m, 2 H, Pr−CH),
4.16 (s, 3 H, NCH3), 2.95 (s, 3 H, COCH3), 2.90 (s, 3 H, COCH3),
i
i
1.79 (d, 12 H, Pr−CH3), 1.76 (d, 12 H, Pr−CH3) ppm. 13C{1H}
NMR (126 MHz, CDCl3): δ = 178.3 (NCOCH3), 165.3 (HEP),
152.9 (NC), 141.3 (Py−C), 140.1 (Py−C), 139.8 (Py−C), 134.2
(Ar−C), 134.1 (Ar−C), 133.0 (Py−C), 126.8 (Py−C), 126.7 (Py−
C), 122.8 (Ar−C), 122.7 (Ar−C), 113.2 (Ar−C), 55.12 (iPr−CH),
55.05 (iPr−CH), 49.2 (NCH3), 30.8 (COCH3), 30.3 (COCH3), 21.4
(iPr−CH3), 21.2 (iPr−CH3), 20.8 (iPr−CH3) ppm. Anal. Calcd for
C21H28Br2N4OPd·0.5CHCl3: C, 38.07, H, 4.23, N, 8.26%. Found: C,
38.39, H, 4.12, N, 7.93%. HRMS (ESI, positive ions): calcd for [M +
Na]+, C21H28Br2N4NaOPd, m/z = 638.9557. Found, m/z = 638.9564.
Dibromido(1,3-diisopropylbenzimidazolin-2-ylidene)(N-(1-
methylpyridin-2-ylidene)acetamide)palladium(II) (10). Follow-
ing route B, the complex was obtained as an orange powder. A
mixture of trans-E- and trans-Z-complex was obtained, and NMR
signals will be listed accordingly as (i) and (ii) with (i) as the
predominant complex. C21H28Br2N4OPd (M = 618.71 g mol−1).
Yield: 0.112 g (0.18 mmol, 60%). 1H NMR (500 MHz, CDCl3, AT):
δ = 8.52 (s, 1 H, 3J = 8.7 Hz, (ii) Py−H), 8.46 (s, 1 H, 3J = 8.7 Hz, (i)
Py−H), 8.20−8.10 (m, 2 H, (ii) Py−H), 8.08−7.96 (m, 1 H, (i) Py−
H), 7.64−7.55 (m, 2 H, (ii) Ar−H), 7.52 (dd, 2 H, 3J = 6.2 Hz, 4J =
3.2 Hz, (i) Ar−H), 7.26−7.20 (dm, 2 H, (ii) Ar−H), 7.16 (dd, 2 H, 3J
3J = 6.4 Hz, 4J = 3.0 Hz, Ar−H), 7.19 (dd, 2 H, J = 6.4 Hz, J = 3.0
3
4
Hz, Ar−H), 6.40 (br. s, 2 H, iPr−CH), 5.41 (s, 2 H, CH2), 2.99 (s, 3
H, COCH3), 1.79 (d, 12 H, Pr−CH3) ppm. 13C{1H} NMR (126
i
MHz, CDCl3, AT): δ = 178.6 (NCOCH3), 165.7 (HEP), 153.3
(NC), 141.1 (Py−C), 140.3 (Py−C), 134.2 (Ar−C), 132.8 (Py−C),
131.4 (Bn−C), 130.8 (Bn−C), 130.5 (Bn−C), 129.2 (Bn−C), 126.9
(Py−C), 122.7 (Ar−C), 113.2 (Ar−C), 65.9 (CH2), 55.1 (iPr−CH),
30.4 (COCH3), 21.4 (iPr−CH3) ppm. Anal. Calcd for
C27H32Br2N4OPd·CHCl3: C, 41.31, H, 4.09, N, 6.88%. Found: C,
41.73, H, 4.11, N, 6.80%. HRMS (ESI, positive ions): calcd for [M +
H]+, C27H33Br2N4OPd, m/z = 693.0050. Found, m/z = 693.0048.
Dibromido(1,3-diisopropylbenzimidazolin-2-ylidene)(N-(1-
benzylpyridin-2-ylidene)acetamide)palladium(II) (13). Both
routes have been applied to synthesize this complex giving similar
yields. The raw product was obtained as yellow powder.
C27H32Br2N4OPd (M = 694.81 g mol−1). Yield: 0.098 g (0.141
mmol, 47%). 1H NMR (400 MHz, CDCl3, AT): δ = 8.46 (dd, 1 H 3J
= 7.5 Hz, Py−H), 7.98 (tm, 1 H, 3J = 7.5 Hz, Py−H), 7.71 (dm, 1 H,
3J = 6.6 Hz, Py−H), 7.54 (dd, 2 H, J = 6.2, J = 3.2 Hz, Ar−H),
7.45−7.39 (m, 4 H, Bn−H), 7.37−7.29 (m, 1 H, Bn−H), 7.18 (dd, 2
3
4
3
3
= 6.2 Hz, J = 3.2 Hz, (i) Ar−H), 6.25 (sept, 2 H, J = 7.1 Hz, (i)
F
Inorg. Chem. XXXX, XXX, XXX−XXX